VFO
BMRN icon

Virtus Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtus Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,921
Closed -$278K – 67
2026
Q1 		$278K Sell
4,921
-1,075
-18% -$62.7K 0.24% 64
2025
Q4 		$356K Buy
+5,996
New +$326K 0.31% 55

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Virtus Family Office's BMRN Position: Q2 2026 in Review

Virtus Family Office sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,921 shares — an estimated $278K sold.

Virtus Family Office first reported a position in BMRN in Q4 2025 and held it in 2 quarters. The position peaked at $356K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Virtus Family Office reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Virtus Family Office sold 4,921 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $278K.
  • Virtus Family Office first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Virtus Family Office's BioMarin Pharmaceuticals position peaked at $356K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Virtus Family Office's 13F filing for Q2 2026, filed 4 Aug 2026.